The most promising predictive biomarker identified in post-hoc analyses to date is IHC for HR23B, which has been shown to be a positive predictive marker for vorinostat in patients with cutaneous T-cell lymphoma [62] and for belinostat (PXD101) in patients with hepatocellular carcinoma [63]. Here, RAD23B is linked to hepatocellular carcinoma.